A Phase 2 interventional study of RPH - 104 and Voltaren® in Gout Attack, sponsored by R-Pharm. Terminated at 11 sites in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-25.
Sponsored by R-Pharm · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary goal of the study was to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.
The study consisted of two periods:
Period 1. In Study Period 1, eligible patients were enrolled in a group of 22 patients and randomized to receive either RPH-104 4 mg or Voltaren® (diclofenac) in the 15:7 ratio (15 RPH-104: 7 Voltaren® (diclofenac)). In order to prevent damage to the gastric and duodenal mucosa caused by Voltaren® (diclofenac), all patients receiving Voltaren® (diclofenac) had to simultaneously take Ortanol® (omeprazole) 20 mg, orally (1 capsule) daily before breakfast throughout the course of Voltaren® (diclofenac) treatment
Period 2. Upon completion of the enrollment of 22 patients, Study Period 2 started. In Period 2, newly enrolled patients were randomly assigned to one of 5 treatment groups: RPH-104 20 mg, 40 mg, 80 mg and 160 mg and active control (Voltaren® (diclofenac)). It was planned to include 14 patients in the RPH-104 groups in Period 2, and 7 patients in the Voltaren® (diclofenac) group.
The enrollment of patients in Period 1 and Period 2 was sequential. There was no pause between the enrollment of patients in Period 1 and Period 2. The study design included screening (24 hours), 11 visits to the study site, and a phone call at the end of the 60-day follow-up period.
Total number of patients which were planned to be enrolled for the study: 85 (15 patients in the group of treatment with RPH-104 4 mg and 14 patients in the each of the other treatment groups). Due to the low patient recruitment rate in the study and the negative impact of the COVID-19 pandemic on the recruitment, at the decision of the sponsor, an interim analysis of the data of 47 patients included in the study as of November 2020 was carried out in order to assess the feasibility of continuing recruitment and further conducting the study.
Patients who did not tolerate pain were allowed to receive a rescue medication, triamcinolone acetonide 40 mg intramuscularly, to intensify therapy 2 hours after the test product was administered. If the attack recurred after the use of the rescue medication, treatment was carried out in accordance with the standard practice of the hospital.
The primary efficacy endpoints were evaluated 72 hours after the end of administration of the test drug. The secondary efficacy endpoints were evaluated for 45 days of the treatment period and follow-up. The safety parameters were evaluated for 60 days of the treatment period and follow-up. Total duration of the study for a volunteer was not more than 70 days.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
This study's enrollment of 47 is below the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Browse Hyperuricemia studies →R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neutropenia, leukopenia, or thrombocytopenia determined based on the following laboratory parameters assessed during the screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
Drug: RPH - 104
Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
Drug: RPH - 104
Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
Drug: RPH - 104
Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
Drug: RPH - 104
Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
Drug: RPH - 104
Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
Drug: Voltaren®
Change in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline
Change in pain intensity in the assessed joint 72 hours after the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) in comparison to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
Time frame: Baseline and Day 4 (72 hours after the initiation of treatment with the test drug)
Change in Pain Intensity in the Assessed Joint in 15, 30, 45 Minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 Hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 Following the Initiation of Treatment and Compared to Baseline
Change in pain intensity in the assessed joint in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) and compared to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
Time frame: Baseline and 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment
Proportion of Patients Who Assessed the Response to Therapy With the Test Drug as "Excellent" or "Good"
Proportion of patients who assessed the response to therapy with the test drug as "Excellent" or "Good" in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug. The patient's response to therapy was assessed in the form of frequency tables by assessment point and therapy group. The rates of the response were specified in the evaluation form as: "Excellent", "Good", "Fair", "Weak", "Poor" (where "excellent" represents the best possible response to treatment and "poor" indicates the worst treatment response).
Time frame: 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment with the test drug
Change in the Rate of Swelling of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
Change in the rate of swelling of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. The rates of swelling were specified in the evaluation form as: "absence" = no swelling, "mild" = palpable swelling, "moderate" = visible swelling, "severe" = bulging outside the joint (where "severe" represented the worst possible degree of swelling and "absence" was the best outcome).
Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Change in the Rate of Tenderness of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
Change in the rate of tenderness of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. Tenderness degrees: "absent" = no tenderness, "mild" = tenderness when touched, "moderate" = pain and flinching, "severe" = pain, flinching and withdrawal of the limb (where "severe" represents the worst possible degree of tenderness and "absent" is the best outcome).
Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Change in the Rate of Erythema of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
Change in the rate of erythema of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline.The rates of "erythema" were specified as "absence", "presence", "impossible to evaluate".
Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Change in the Rate of Movement Restrictions in the Specified Timeframes After Initiation of Treatment
Change in the rate of movement restrictions in the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. For the assessment, the categorical scale consistent with the Form for evaluation (Investigator's Assessment) of the restriction of movements was used. The rates of movement restrictions (amplitude of movements) were specified in the evaluation form as "1 - Normal range", "2 - Slightly limited range", " 3 - Moderately limited range" ,"4 - Severely limited range" and "5 - Joint movement is impossible " (where higher score means worse outcome).
Time frame: Baseline and in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Time to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the Baseline
Time to achieve the 50% decrease in pain intensity in the assessed joint relative to the baseline VAS level. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)). The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
Time frame: Baseline and one of the pain intensity measurements in accordance with the schedule: 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment
Time to Use of the Rescue Medication
Time to use of the rescue medication was calculated as the time in hours from the date/time of administration (first dose) of the investigational product to the date/time of the first use of the rescue medication.
Time frame: from the date/time of IP administration (first dose) to the date/time of the first use of the rescue medication, up to day 60
Proportion of Patients Who Received a Rescue Therapy Agent
The proportion of patients who received the rescue medication within 72 hours of starting the investigational product therapy
Time frame: 72 hours after the initiation of treatment with the test drug
Proportion of Patients Who Received a Rescue Therapy Agent
The proportion of patients who received the rescue medication over the entire treatment period
Time frame: up to day 60
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Disability Index
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. (The result for each of the 8 categories ("Dressing and Grooming", "Arising", "Eating", "Walking", "Hygiene", "Reach", "Grip", "Activities") of the HAQ questionnaire was calculated as the maximum score of responses (on an ordinal scale from 0 (best) to 3 (worst): without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3)) to questions included in this category. If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2". The sum of points for the evaluated categories was calculated and divided by the number of categories, which gives a disability index in the range of 0 to 3.)
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Arising
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Eating
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Walking
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Hygiene
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Grip
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Pharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration
Including area under the plasma concentration-time curve over the dosing interval (AUC0-tau)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Pharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration
Including Area under the active substance concentration-time curve from zero (before drug administration) to infinity (AUC0-∞)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Pharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration
Including Maximum concentration of the active substance (Cmax)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Pharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration
Including elimination constant (Kel)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Pharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration
Including Time to reach maximum concentration of the active substance (tmax)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Pharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration
Including terminal half-life (T 1/2)
Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Change in the Serum Rate of High-sensitive CRP (Hs-CRP) in Specified Timeframes
Change in the serum rate of high-sensitive CRP (hs-CRP) in 24, 72 hours, on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug compared to baseline
Time frame: Baseline and in 24, 72 hours, on Days 5, 6, 15, 29 and 45 after the initiation of treatment with the test drug
Change in the Rate of Serum Amyloid Protein A in the Specified Timeframes
Change in the rate of serum amyloid protein A in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: IL-1α
Change in the serum rates of IL-1α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: IL-1β
Change in the serum rates of IL-1β in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: Interleukin -1 Receptor Antagonist (IL-1RA)
Change in the serum rates of IL-1RA in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: IL-6
Change in the serum rates of IL-6 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: IL-8
Change in the serum rates of IL-8 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Change in the Serum Rates of Cytokines: Tumor Necrosis Factor (TNF-α)
Change in the serum rates of TNF-α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Enrollment was conducted at 11 clinical sites in Russian Federation. 54 subjects were screened and 47 subjects were enrolled (randomized) and treated, 44 subjects completed the study. The Safety Population and Efficacy Population included data from all 47 randomized patients to assess safety, treatment efficacy and pharmacodynamics.
| Milestone | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Started | 15 | 6 | 6 | 6 | 5 | 9 |
| Completed | 15 | 5 | 6 | 5 | 5 | 8 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Closure of city borders because of covid-19 quarantine | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 epidemiological situation | 0 | 0 | 0 | 1 | 0 | 0 |
Change in pain intensity in the assessed joint 72 hours after the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) in comparison to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
| mm (VAS scale) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Change in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline | -7.88 (-22.26 to 6.50) | -38.56 (-60.39 to -16.72) | -19.80 (-41.83 to 2.22) | -33.39 (-55.53 to -11.24) | -30.55 (-54.46 to -6.64) | -36.51 (-55.11 to -17.90) |
Change in pain intensity in the assessed joint in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) and compared to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
| mm (VAS scale) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Day 1/15 minutes | -2.00 (-6.38 to 2.38) | -6.97 (-13.81 to -0.14) | -5.91 (-12.76 to 0.94) | -1.52 (-8.39 to 5.34) | -5.75 (-13.23 to 1.74) | -3.78 (-9.44 to 1.88) |
| Day 1/30 minutes | -10.00 (-16.81 to -3.19) | -14.16 (-24.87 to -3.45) | -6.43 (-17.15 to 4.29) | -5.19 (-15.92 to 5.54) | -10.57 (-22.30 to 1.16) | -5.45 (-14.24 to 3.35) |
| Day 1/45 minutes | -16.20 (-24.71 to -7.69) | -16.14 (-29.55 to -2.73) | -7.91 (-21.33 to 5.51) | -9.36 (-22.78 to 4.07) | -11.77 (-26.45 to 2.92) | -8.56 (-19.55 to 2.43) |
| Day 1/ 1 hour | -19.67 (-30.12 to -9.21) | -15.81 (-32.30 to 0.69) | -11.76 (-28.27 to 4.74) | -12.52 (-29.03 to 3.99) | -15.99 (-34.06 to 2.09) | -12.67 (-26.17 to 0.83) |
| Day 1/ 1.5 hours | -22.47 (-32.96 to -11.97) | -15.14 (-31.70 to 1.42) | -21.26 (-37.82 to -4.70) | -14.69 (-31.26 to 1.88) | -17.79 (-35.92 to 0.35) | -13.67 (-27.22 to -0.12) |
| Day 1/ 2 hours | -22.07 (-33.65 to -10.48) | -25.14 (-43.42 to -6.86) | -24.63 (-42.92 to -6.34) | -13.86 (-32.15 to 4.44) | -19.59 (-39.62 to 0.44) | -20.56 (-35.52 to -5.60) |
| Day 1/ 4 hours | -21.87 (-34.63 to -9.10) | -27.27 (-47.43 to -7.12) | -21.44 (-41.61 to -1.28) | -14.36 (-34.52 to 5.81) | -20.35 (-42.43 to 1.73) | -22.67 (-39.15 to -6.19) |
| Day 1/ 8 hours | -14.20 (-27.05 to -1.35) | -29.61 (-49.89 to -9.32) | -18.93 (-39.22 to 1.36) | -16.52 (-36.82 to 3.77) | -25.35 (-47.57 to -3.13) | -25.67 (-42.26 to -9.08) |
| Day 2 | -10.60 (-23.27 to 2.07) | -37.77 (-57.77 to -17.78) | -20.94 (-40.95 to -0.94) | -25.52 (-45.53 to -5.52) | -30.35 (-52.25 to -8.44) | -30.34 (-46.69 to -13.98) |
| Day 3 | -3.33 (-16.21 to 9.54) | -35.77 (-56.10 to -15.45) | -27.94 (-48.28 to -7.61) | -34.69 (-55.03 to -14.35) | -30.15 (-52.41 to -7.88) | -38.67 (-55.29 to -22.05) |
| Day 4 | -6.67 (-20.38 to 7.05) | -38.77 (-60.43 to -17.11) | -18.91 (-40.58 to 2.76) | -34.52 (-56.19 to -12.85) | -30.75 (-54.47 to -7.02) | -38.12 (-55.83 to -20.40) |
| Day 5 | -4.73 (-18.62 to 9.15) | -31.27 (-53.20 to -9.35) | -13.64 (-35.57 to 8.28) | -35.86 (-57.79 to -13.92) | -31.35 (-55.36 to -7.33) | -42.78 (-60.71 to -24.86) |
| Day 6 | -4.80 (-18.42 to 8.82) | -34.44 (-55.95 to -12.93) | -12.43 (-33.95 to 9.09) | -22.86 (-44.38 to -1.33) | -29.15 (-52.71 to -5.58) | -42.45 (-60.04 to -24.86) |
| Day 10 | -6.73 (-21.29 to 7.82) | -37.27 (-60.26 to -14.29) | -12.43 (-35.42 to 10.57) | -23.52 (-46.52 to -0.53) | -29.15 (-54.33 to -3.96) | -37.78 (-56.57 to -18.99) |
| Day 15 | -4.13 (-18.21 to 9.94) | -41.77 (-64.00 to -19.55) | -12.41 (-34.64 to 9.82) | -12.69 (-34.93 to 9.55) | -28.95 (-53.30 to -4.60) | -38.34 (-56.51 to -20.16) |
| Day 18 | -4.07 (-18.18 to 10.05) | -42.61 (-64.90 to -20.31) | -12.74 (-35.04 to 9.55) | -12.69 (-34.99 to 9.61) | -29.75 (-54.17 to -5.33) | -28.45 (-46.67 to -10.22) |
| Day 22 | -3.20 (-17.43 to 11.03) | -44.61 (-67.08 to -22.14) | -13.58 (-36.05 to 8.90) | -12.69 (-35.17 to 9.79) | -28.35 (-52.96 to -3.73) | -30.34 (-48.71 to -11.97) |
| Day 29 | -4.07 (-18.36 to 10.23) | -44.94 (-67.52 to -22.36) | -13.58 (-36.16 to 9.01) | -12.69 (-35.28 to 9.90) | -17.95 (-42.68 to 6.79) | -23.89 (-42.35 to -5.43) |
| Day 45 | -2.60 (-16.67 to 11.48) | -46.94 (-69.17 to -24.71) | -13.58 (-35.81 to 8.66) | -12.69 (-34.93 to 9.55) | -19.75 (-44.09 to 4.60) | -23.34 (-41.51 to -5.16) |
Proportion of patients who assessed the response to therapy with the test drug as "Excellent" or "Good" in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug. The patient's response to therapy was assessed in the form of frequency tables by assessment point and therapy group. The rates of the response were specified in the evaluation form as: "Excellent", "Good", "Fair", "Weak", "Poor" (where "excellent" represents the best possible response to treatment and "poor" indicates the worst treatment response).
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Day 1/15 minutes | 0 | 1 | 0 | 1 | 0 | 1 |
| Day 1/30 minutes | 2 | 1 | 0 | 1 | 0 | 2 |
| Day 1/45 minutes | 3 | 1 | 0 | 2 | 0 | 2 |
| Day 1/ 1 hour | 3 | 0 | 0 | 2 | 0 | 1 |
| Day 1/ 1.5 hours | 3 | 0 | 1 | 1 | 0 | 1 |
| Day 1/ 2 hours | 3 | 0 | 1 | 1 | 0 | 1 |
| Day 1/ 4 hours | 2 | 0 | 2 | 1 | 1 | 2 |
| Day 1/ 8 hours | 2 | 1 | 2 | 1 | 2 | 4 |
| Day 2 | 1 | 0 | 2 | 1 | 2 | 2 |
| Day 3 | 1 | 1 | 2 | 1 | 2 | 5 |
| Day 4 | 1 | 1 | 1 | 3 | 2 | 6 |
| Day 5 | 1 | 1 | 1 | 3 | 2 | 6 |
| Day 6 | 1 | 2 | 1 | 2 | 2 | 6 |
| Day 10 | 1 | 1 | 1 | 2 | 2 | 6 |
| Day 15 | 1 | 2 | 1 | 1 | 2 | 6 |
| Day 18 | 1 | 1 | 1 | 1 | 2 | 4 |
| Day 22 | 0 | 2 | 1 | 1 | 2 | 5 |
| Day 29 | 1 | 2 | 1 | 1 | 1 | 3 |
| Day 45 | 0 | 1 | 1 | 1 | 1 | 3 |
Change in the rate of swelling of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. The rates of swelling were specified in the evaluation form as: "absence" = no swelling, "mild" = palpable swelling, "moderate" = visible swelling, "severe" = bulging outside the joint (where "severe" represented the worst possible degree of swelling and "absence" was the best outcome).
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline — absence | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline — mild | 1 | 0 | 0 | 0 | 0 | 1 |
| Baseline — moderate | 9 | 3 | 2 | 4 | 1 | 5 |
| Baseline — severe | 5 | 3 | 4 | 2 | 4 | 3 |
| Day 2/ 24 hours — absence | 1 | 0 | 0 | 1 | 1 | 0 |
| Day 2/ 24 hours — mild | 2 | 2 | 1 | 1 | 1 | 5 |
| Day 2/ 24 hours — moderate | 8 | 3 | 2 | 3 | 2 | 3 |
| Day 2/ 24 hours — severe | 1 | 0 | 3 | 0 | 0 | 0 |
| Day 3/ 48 hours — absence | 1 | 1 | 0 | 3 | 1 | 2 |
| Day 3/ 48 hours — mild | 1 | 3 | 1 | 0 | 0 | 5 |
| Day 3/ 48 hours — moderate | 0 | 1 | 1 | 1 | 2 | 0 |
| Day 3/ 48 hours — severe | 0 | 0 | 3 | 0 | 0 | 0 |
| Day 4/ 72 hours — absence | 1 | 2 | 1 | 3 | 1 | 4 |
| Day 4/ 72 hours — mild | 1 | 2 | 0 | 0 | 1 | 2 |
| Day 4/ 72 hours — moderate | 0 | 1 | 0 | 0 | 1 | 1 |
| Day 4/ 72 hours — severe | 0 | 0 | 2 | 0 | 0 | 0 |
| Day 5 — absence | 1 | 2 | 1 | 3 | 1 | 4 |
| Day 5 — mild | 1 | 1 | 0 | 0 | 1 | 2 |
| Day 5 — moderate | 0 | 1 | 0 | 0 | 1 | 1 |
| Day 5 — severe | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 6 — absence | 1 | 2 | 1 | 2 | 1 | 4 |
| Day 6 — mild | 1 | 2 | 0 | 0 | 2 | 3 |
| Day 6 — moderate | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 6 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 10 — absence | 1 | 3 | 1 | 2 | 2 | 4 |
| Day 10 — mild | 1 | 0 | 0 | 0 | 1 | 0 |
| Day 10 — moderate | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 10 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — absence | 1 | 4 | 1 | 1 | 2 | 6 |
| Day 15 — mild | 0 | 0 | 0 | 0 | 1 | 0 |
| Day 15 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — absence | 1 | 2 | 1 | 1 | 2 | 2 |
| Day 18 — mild | 0 | 1 | 0 | 0 | 1 | 0 |
| Day 18 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — absence | 1 | 3 | 1 | 1 | 1 | 2 |
| 22 — mild | 0 | 1 | 0 | 0 | 1 | 0 |
| 22 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 — absence | 1 | 4 | 1 | 1 | 0 | 4 |
| 29 — mild | 0 | 0 | 0 | 0 | 1 | 0 |
| 29 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — absence | 0 | 3 | 1 | 1 | 0 | 4 |
| 45 — mild | 1 | 0 | 0 | 0 | 1 | 0 |
| 45 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
Change in the rate of tenderness of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. Tenderness degrees: "absent" = no tenderness, "mild" = tenderness when touched, "moderate" = pain and flinching, "severe" = pain, flinching and withdrawal of the limb (where "severe" represents the worst possible degree of tenderness and "absent" is the best outcome).
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline — absence | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline — mild | 1 | 1 | 0 | 0 | 0 | 0 |
| Baseline — moderate | 12 | 4 | 3 | 4 | 2 | 6 |
| Baseline — severe | 2 | 1 | 3 | 2 | 3 | 3 |
| Day 2/ 24 hours — absence | 1 | 0 | 0 | 1 | 2 | 0 |
| Day 2/ 24 hours — mild | 4 | 5 | 3 | 1 | 1 | 6 |
| Day 2/ 24 hours — moderate | 6 | 0 | 1 | 3 | 1 | 2 |
| Day 2/ 24 hours — severe | 1 | 0 | 2 | 0 | 0 | 0 |
| Day 3/ 48 hours — absence | 1 | 0 | 0 | 1 | 1 | 1 |
| Day 3/ 48 hours — mild | 1 | 5 | 2 | 2 | 2 | 6 |
| Day 3/ 48 hours — moderate | 0 | 0 | 1 | 1 | 0 | 0 |
| Day 3/ 48 hours — severe | 0 | 0 | 2 | 0 | 0 | 0 |
| Day 4/ 72 hours — absence | 1 | 2 | 0 | 2 | 1 | 3 |
| Day 4/ 72 hours — mild | 1 | 3 | 1 | 1 | 2 | 4 |
| Day 4/ 72 hours — moderate | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 4/ 72 hours — severe | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 5 — absence | 1 | 2 | 1 | 3 | 1 | 3 |
| Day 5 — mild | 1 | 2 | 0 | 0 | 1 | 4 |
| Day 5 — moderate | 0 | 0 | 0 | 0 | 1 | 0 |
| Day 5 — severe | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 6 — absence | 1 | 2 | 1 | 2 | 1 | 4 |
| Day 6 — mild | 1 | 2 | 0 | 0 | 2 | 3 |
| Day 6 — moderate | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 6 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 10 — absence | 1 | 3 | 1 | 2 | 2 | 4 |
| Day 10 — mild | 1 | 0 | 0 | 0 | 1 | 0 |
| Day 10 — moderate | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 10 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — absence | 1 | 3 | 1 | 1 | 2 | 5 |
| Day 15 — mild | 0 | 1 | 0 | 0 | 1 | 1 |
| Day 15 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — absence | 1 | 3 | 1 | 1 | 2 | 1 |
| Day 18 — mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Day 18 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — absence | 0 | 3 | 1 | 1 | 1 | 1 |
| 22 — mild | 1 | 1 | 0 | 0 | 1 | 1 |
| 22 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 — absence | 1 | 3 | 1 | 1 | 1 | 3 |
| 29 — mild | 0 | 1 | 0 | 0 | 0 | 1 |
| 29 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — absence | 0 | 3 | 1 | 1 | 0 | 4 |
| 45 — mild | 1 | 0 | 0 | 0 | 1 | 0 |
| 45 — moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — severe | 0 | 0 | 0 | 0 | 0 | 0 |
Change in the rate of erythema of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline.The rates of "erythema" were specified as "absence", "presence", "impossible to evaluate".
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline — absence | 3 | 0 | 0 | 0 | 0 | 2 |
| Baseline — presence | 12 | 6 | 6 | 5 | 5 | 7 |
| Baseline — evaluation impossible | 0 | 0 | 0 | 1 | 0 | 0 |
| Day 2/ 24 hours — absence | 5 | 2 | 1 | 1 | 2 | 2 |
| Day 2/ 24 hours — presence | 7 | 3 | 4 | 4 | 2 | 6 |
| Day 2/ 24 hours — evaluation impossible | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 3/ 48 hours — absence | 2 | 4 | 2 | 3 | 1 | 5 |
| Day 3/ 48 hours — presence | 0 | 1 | 2 | 1 | 2 | 2 |
| Day 3/ 48 hours — evaluation impossible | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 4/ 72 hours — absence | 2 | 4 | 1 | 3 | 2 | 7 |
| Day 4/ 72 hours — presence | 0 | 1 | 2 | 0 | 1 | 0 |
| Day 4/ 72 hours — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 5 — absence | 2 | 4 | 1 | 3 | 3 | 7 |
| Day 5 — presence | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 5 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 6 — absence | 2 | 4 | 1 | 2 | 3 | 7 |
| Day 6 — presence | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 6 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 10 — absence | 2 | 3 | 1 | 2 | 3 | 4 |
| Day 10 — presence | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 10 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — absence | 1 | 4 | 1 | 1 | 3 | 6 |
| Day 15 — presence | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — absence | 1 | 3 | 1 | 1 | 3 | 2 |
| Day 18 — presence | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — absence | 1 | 4 | 1 | 1 | 2 | 2 |
| 22 — presence | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 — absence | 1 | 3 | 1 | 1 | 1 | 4 |
| 29 — presence | 0 | 1 | 0 | 0 | 0 | 0 |
| 29 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — absence | 1 | 3 | 1 | 1 | 1 | 4 |
| 45 — presence | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 — evaluation impossible | 0 | 0 | 0 | 0 | 0 | 0 |
Change in the rate of movement restrictions in the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. For the assessment, the categorical scale consistent with the Form for evaluation (Investigator's Assessment) of the restriction of movements was used. The rates of movement restrictions (amplitude of movements) were specified in the evaluation form as "1 - Normal range", "2 - Slightly limited range", " 3 - Moderately limited range" ,"4 - Severely limited range" and "5 - Joint movement is impossible " (where higher score means worse outcome).
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline — 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline — 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline — 3 | 5 | 2 | 1 | 3 | 2 | 6 |
| Baseline — 4 | 9 | 4 | 5 | 2 | 2 | 3 |
| Baseline — 5 | 1 | 0 | 0 | 1 | 1 | 0 |
| Day 2/ 24 hours — 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 2/ 24 hours — 2 | 0 | 1 | 0 | 2 | 2 | 4 |
| Day 2/ 24 hours — 3 | 7 | 3 | 3 | 2 | 1 | 3 |
| Day 2/ 24 hours — 4 | 3 | 1 | 2 | 1 | 1 | 1 |
| Day 2/ 24 hours — 5 | 1 | 0 | 1 | 0 | 0 | 0 |
| Day 3/ 48 hours — 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Day 3/ 48 hours — 2 | 1 | 5 | 2 | 2 | 1 | 4 |
| Day 3/ 48 hours — 3 | 1 | 0 | 1 | 1 | 0 | 2 |
| Day 3/ 48 hours — 4 | 0 | 0 | 1 | 0 | 1 | 0 |
| Day 3/ 48 hours — 5 | 0 | 0 | 1 | 0 | 0 | 0 |
| Day 4/ 72 hours — 1 | 1 | 2 | 1 | 2 | 1 | 2 |
| Day 4/ 72 hours — 2 | 0 | 3 | 0 | 1 | 1 | 5 |
| Day 4/ 72 hours — 3 | 1 | 0 | 1 | 0 | 0 | 0 |
| Day 4/ 72 hours — 4 | 0 | 0 | 1 | 0 | 1 | 0 |
| Day 4/ 72 hours — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 5 — 1 | 1 | 3 | 1 | 3 | 1 | 3 |
| Day 5 — 2 | 0 | 1 | 0 | 0 | 1 | 4 |
| Day 5 — 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 5 — 4 | 0 | 0 | 1 | 0 | 1 | 0 |
| Day 5 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 6 — 1 | 1 | 3 | 1 | 2 | 1 | 5 |
| Day 6 — 2 | 0 | 1 | 0 | 0 | 1 | 2 |
| Day 6 — 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 6 — 4 | 0 | 0 | 1 | 0 | 1 | 0 |
| Day 6 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 10 — 1 | 1 | 3 | 1 | 2 | 2 | 3 |
| Day 10 — 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Day 10 — 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 10 — 4 | 0 | 0 | 1 | 0 | 1 | 0 |
| Day 10 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — 1 | 1 | 3 | 1 | 1 | 2 | 5 |
| Day 15 — 2 | 0 | 1 | 0 | 0 | 0 | 1 |
| Day 15 — 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Day 15 — 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 15 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — 1 | 0 | 3 | 1 | 1 | 2 | 2 |
| Day 18 — 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Day 18 — 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 18 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 22 — 1 | 0 | 3 | 1 | 1 | 1 | 2 |
| Day 22 — 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Day 22 — 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Day 22 — 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 22 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 29 — 1 | 0 | 3 | 1 | 1 | 0 | 4 |
| Day 29 — 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Day 29 — 3 | 0 | 1 | 0 | 0 | 1 | 0 |
| Day 29 — 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 29 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 45 — 1 | 0 | 3 | 1 | 1 | 0 | 4 |
| Day 45 — 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 45 — 3 | 1 | 0 | 0 | 0 | 1 | 0 |
| Day 45 — 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 45 — 5 | 0 | 0 | 0 | 0 | 0 | 0 |
Time to achieve the 50% decrease in pain intensity in the assessed joint relative to the baseline VAS level. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)). The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".
| hours | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Time to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the Baseline | NA (0.8 to NA) | 6.0 (0.3 to NA) | NA (1.5 to NA) | NA (0.8 to NA) | 8.0 (4.0 to NA) | 47.3 (0.8 to NA) |
Time to use of the rescue medication was calculated as the time in hours from the date/time of administration (first dose) of the investigational product to the date/time of the first use of the rescue medication.
| hours | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Time to Use of the Rescue Medication | 23.7 (21.3 to 24.5) | NA (3.1 to NA) | 71.8 (24.4 to NA) | 84.6 (22.7 to NA) | NA (3.0 to NA) | NA (4.4 to NA) |
The proportion of patients who received the rescue medication within 72 hours of starting the investigational product therapy
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Proportion of Patients Who Received a Rescue Therapy Agent | 12 | 1 | 3 | 3 | 2 | 2 |
The proportion of patients who received the rescue medication over the entire treatment period
| Participants | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Proportion of Patients Who Received a Rescue Therapy Agent | 13 | 1 | 4 | 4 | 2 | 3 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. (The result for each of the 8 categories ("Dressing and Grooming", "Arising", "Eating", "Walking", "Hygiene", "Reach", "Grip", "Activities") of the HAQ questionnaire was calculated as the maximum score of responses (on an ordinal scale from 0 (best) to 3 (worst): without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3)) to questions included in this category. If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2". The sum of points for the evaluated categories was calculated and divided by the number of categories, which gives a disability index in the range of 0 to 3.)
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.3 ± 0.802 | 1.23 ± 0.578 | 1.75 ± 0.806 | 1.1 ± 0.649 | 1.6 ± 0.615 | 1.32 ± 0.577 |
| Change Day 15 | -0.75 ± NA | -0.63 ± 0.685 | -0.88 ± NA | -0.63 ± NA | -1.06 ± 0.619 | -0.56 ± 0.342 |
| Change Day 29 | -0.13 ± NA | -1.09 ± 0.672 | -1.25 ± NA | -0.63 ± NA | -0.5 ± 0.53 | -0.38 ± 0.144 |
| Change Day 45 | -0.38 ± NA | -1.42 ± 0.382 | -1.38 ± NA | -0.63 ± NA | -0.56 ± 0.619 | -0.44 ± 0.298 |
Including area under the plasma concentration-time curve over the dosing interval (AUC0-tau)
| h*ng/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration | 38000 ± 124 | 762000 ± 152 | 845000 ± 45 | 1620000 ± 36.5 | 3230000 ± 38.2 |
Including Area under the active substance concentration-time curve from zero (before drug administration) to infinity (AUC0-∞)
| h*ng/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration | 47900 ± 97.9 | 816000 ± 155 | 901000 ± 44.3 | 1720000 ± 37.1 | 3380000 ± 38.1 |
Including Maximum concentration of the active substance (Cmax)
| ng/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration | 142 ± 110 | 2220 ± 155 | 2380 ± 47.7 | 4860 ± 18 | 9760 ± 38.2 |
Including elimination constant (Kel)
| 1/h | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration | 0.00298 ± 0.000573 | 0.00314 ± 0.000622 | 0.00304 ± 0.000241 | 0.00317 ± 0.000575 | 0.00294 ± 0.000311 |
Including Time to reach maximum concentration of the active substance (tmax)
| hours | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration | 93.7 (8 to 120) | 47.5 (21.3 to 72.1) | 84.8 (47.1 to 120) | 82.7 (24 to 122) | 94.4 (72 to 96.1) |
Including terminal half-life (T 1/2)
| hours | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration | 248 (153 to 285) | 235 (170 to 274) | 223 (205 to 256) | 231 (168 to 264) | 241 (212 to 261) |
Change in the serum rate of high-sensitive CRP (hs-CRP) in 24, 72 hours, on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug compared to baseline
| mg/L | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 36.673 ± 31.3545 | 8.295 ± 6.6212 | 10.105 ± 14.2834 | 37.908 ± 25.5594 | 35.396 ± 32.4800 | 15.769 ± 18.0878 |
| Day 2/ 24 hours | 35.468 ± 32.2025 | 20.338 ± 33.3728 | 24.483 ± 16.3543 | 28.864 ± 16.1194 | 12.000 ± 11.5518 | 22.716 ± 26.9958 |
| Day 4/ 72 hours | 33.894 ± 35.0873 | 3.408 ± 0.8120 | 12.900 ± 9.3579 | 11.846 ± 6.1780 | 8.678 ± 10.5037 | 9.279 ± 8.1642 |
| Day 5 | 32.279 ± 32.6858 | 3.090 ± 0.9076 | 7.142 ± 5.7071 | 8.696 ± 3.6468 | 6.178 ± 6.4262 | 8.877 ± 6.3308 |
| Day 6 | 29.065 ± 28.1288 | 2.710 ± 1.6140 | 3.650 ± 2.8445 | 4.604 ± 1.3871 | 3.190 ± 3.0165 | 8.417 ± 7.0440 |
| Day 15 | 21.017 ± 28.4384 | 2.642 ± 1.4322 | 3.304 ± 5.8018 | 5.115 ± 3.5382 | 4.042 ± 6.1199 | 6.579 ± 4.4134 |
| Day 29 | 16.811 ± 26.3922 | 7.532 ± 13.0615 | 2.750 ± 2.9068 | 5.014 ± 2.8480 | 10.998 ± 17.3463 | 7.595 ± 7.9870 |
| Day 45 | 24.958 ± 29.4450 | 3.570 ± 2.1907 | 2.445 ± 1.8315 | 3.093 ± 0.5652 | 14.500 ± 19.2882 | 11.734 ± 11.4627 |
Change in the rate of serum amyloid protein A in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| ng/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 13493.687 ± 14565.0449 | 2516.606 ± 1367.7981 | 16764.020 ± 14525.1072 | 16168.130 ± 12937.7377 | 16291.605 ± 17949.6741 | 5033.151 ± 3384.3761 |
| Day 2/ 24 hours | 17424.060 ± 17167.2073 | 11078.300 ± 19281.3822 | 20104.555 ± 15608.3760 | 15581.486 ± 13271.7115 | 3659.778 ± 3244.2099 | 7294.631 ± 5163.5001 |
| Day 4/ 72 hours | 17588.735 ± 16623.4301 | 1171.203 ± 400.3851 | 12162.612 ± 12060.2753 | 14419.760 ± 11828.2546 | 10596.423 ± 16813.3253 | 7362.322 ± 9834.7459 |
| Day 5 | 17360.201 ± 15874.5237 | 1195.975 ± 393.6981 | 5680.190 ± 5708.9022 | 8228.272 ± 7624.1329 | 5952.460 ± 10455.6856 | 8252.633 ± 8121.6203 |
| Day 6 | 18553.955 ± 15454.2373 | 1847.923 ± 1646.0125 | 4781.173 ± 6120.5728 | 5799.608 ± 5562.9980 | 6117.777 ± 8569.9756 | 6165.779 ± 5356.4841 |
| Day 15 | 9272.782 ± 11297.9676 | 1525.612 ± 502.8845 | 8899.982 ± 17399.0042 | 4582.338 ± 5995.5993 | 2732.598 ± 1325.3698 | 6031.146 ± 10261.9489 |
| Day 29 | 8918.439 ± 12001.1492 | 4255.756 ± 6845.1947 | 1645.107 ± 1044.8811 | 3626.702 ± 2740.1283 | 3618.843 ± 3147.2319 | 3779.410 ± 2727.9500 |
| Day 45 | 13858.845 ± 16512.5575 | 2086.198 ± 2799.5039 | 1269.680 ± 695.3511 | 1567.040 ± 1421.4541 | 9885.230 ± 15228.9607 | 7289.553 ± 7189.8429 |
Change in the serum rates of IL-1α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.752 ± 1.5390 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 2/ 24 hours | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.097 ± 0.0163 | 1.782 ± 1.5474 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 4/ 72 hours | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.688 ± 1.3372 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 5 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.790 ± 1.5652 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 6 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.612 ± 1.1672 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 15 | 1.132 ± 0.1525 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 29 | 1.097 ± 0.0258 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
| Day 45 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 | 1.090 ± 0.0000 |
Change in the serum rates of IL-1β in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 39.035 ± 138.5078 | 1.080 ± 1.9351 | 0.290 ± 0.0000 | 2.558 ± 3.5248 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 2/ 24 hours | 33.885 ± 128.9519 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 1.100 ± 1.8112 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 4/ 72 hours | 33.759 ± 128.9859 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 2.112 ± 4.0741 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 5 | 33.753 ± 128.9873 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 6 | 33.998 ± 128.9231 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 2.362 ± 4.6331 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 15 | 38.730 ± 138.5974 | 1.222 ± 2.0840 | 0.290 ± 0.0000 | 1.965 ± 3.3500 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 29 | 33.811 ± 128.9724 | 1.320 ± 2.3032 | 0.417 ± 0.3103 | 1.746 ± 3.2557 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
| Day 45 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 | 0.290 ± 0.0000 |
Change in the serum rates of IL-1RA in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 2400.500 ± 1495.1100 | 1448.978 ± 527.8658 | 1671.010 ± 1225.2673 | 2240.155 ± 937.1988 | 2619.456 ± 2706.3397 | 2090.721 ± 1240.5717 |
| Day 2/ 24 hours | 1700.180 ± 1448.4981 | 229.842 ± 291.9887 | 153.098 ± 145.3780 | 29.990 ± 0.0000 | 29.990 ± 0.0000 | 2483.891 ± 1786.0361 |
| Day 4/ 72 hours | 1295.743 ± 916.8659 | 156.216 ± 110.6281 | 140.108 ± 123.8956 | 157.654 ± 227.2334 | 29.990 ± 0.0000 | 2297.651 ± 1361.7429 |
| Day 5 | 1364.993 ± 1106.8245 | 187.223 ± 109.9846 | 154.463 ± 124.6690 | 87.214 ± 79.7269 | 29.990 ± 0.0000 | 2417.991 ± 1416.8428 |
| Day 6 | 1407.230 ± 927.8243 | 214.610 ± 125.9518 | 203.688 ± 133.0562 | 180.492 ± 112.2664 | 29.990 ± 0.0000 | 2426.761 ± 1452.6687 |
| Day 15 | 1620.332 ± 935.4363 | 374.900 ± 96.9459 | 474.542 ± 214.5880 | 645.085 ± 300.6542 | 257.492 ± 166.0738 | 2249.794 ± 1459.3243 |
| Day 29 | 1928.417 ± 1048.0875 | 563.892 ± 142.6097 | 583.062 ± 269.1237 | 686.992 ± 305.9470 | 471.178 ± 267.8262 | 1870.815 ± 1032.8765 |
| Day 45 | 1806.647 ± 858.8185 | 915.010 ± 177.2813 | 808.212 ± 354.6509 | 711.997 ± 285.9941 | 518.063 ± 201.1455 | 1969.547 ± 1352.6193 |
Change in the serum rates of IL-6 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 26.035 ± 39.1257 | 5.005 ± 4.6022 | 34.307 ± 54.3264 | 5.623 ± 6.8564 | 13.666 ± 11.9695 | 6.058 ± 6.9686 |
| Day 2/ 24 hours | 27.030 ± 42.9908 | 2.084 ± 1.8930 | 37.788 ± 72.3187 | 6.284 ± 11.1153 | 9.065 ± 12.5843 | 2.361 ± 1.2039 |
| Day 4/ 72 hours | 14.943 ± 29.9008 | 2.236 ± 1.8533 | 2.145 ± 0.9961 | 3.142 ± 3.7290 | 4.698 ± 7.3223 | 1.702 ± 1.1067 |
| Day 5 | 23.999 ± 37.5678 | 2.695 ± 2.2949 | 2.378 ± 1.9432 | 1.396 ± 0.5031 | 4.905 ± 7.5114 | 1.823 ± 1.6473 |
| Day 6 | 8.391 ± 13.3742 | 3.565 ± 3.5282 | 2.965 ± 3.4991 | 1.272 ± 0.3636 | 6.220 ± 9.8491 | 2.157 ± 2.1250 |
| Day 15 | 10.595 ± 14.4444 | 2.870 ± 1.5838 | 2.434 ± 1.7929 | 1.793 ± 0.5907 | 12.858 ± 25.3149 | 2.036 ± 1.2089 |
| Day 29 | 18.643 ± 50.4658 | 2.758 ± 1.7315 | 3.278 ± 4.2245 | 1.482 ± 0.5334 | 17.903 ± 31.1335 | 5.304 ± 7.4387 |
| Day 45 | 6.466 ± 9.1261 | 4.608 ± 5.8999 | 3.370 ± 4.5051 | 1.537 ± 0.3911 | 3.753 ± 1.6094 | 2.607 ± 1.9663 |
Change in the serum rates of IL-8 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 12.384 ± 5.8297 | 21.964 ± 24.8759 | 9.277 ± 4.5347 | 18.305 ± 21.8921 | 12.318 ± 12.5702 | 10.863 ± 7.1505 |
| Day 2/ 24 hours | 8.228 ± 7.1217 | 9.304 ± 9.7609 | 9.030 ± 5.5014 | 12.304 ± 9.9136 | 2.668 ± 1.3550 | 17.141 ± 13.6494 |
| Day 4/ 72 hours | 15.601 ± 19.4714 | 8.708 ± 5.8951 | 9.020 ± 6.2030 | 5.952 ± 4.4991 | 8.148 ± 5.6025 | 15.980 ± 11.7350 |
| Day 5 | 13.521 ± 7.8988 | 4.313 ± 2.6941 | 8.032 ± 4.9402 | 10.518 ± 6.8098 | 11.190 ± 4.4376 | 15.188 ± 12.3696 |
| Day 6 | 16.969 ± 16.9723 | 8.015 ± 4.6897 | 7.937 ± 5.3199 | 7.594 ± 5.9449 | 10.745 ± 6.3010 | 19.881 ± 21.0673 |
| Day 15 | 9.765 ± 9.3536 | 20.884 ± 31.6507 | 11.520 ± 7.4313 | 16.395 ± 19.5556 | 3.060 ± 2.3926 | 34.770 ± 66.4033 |
| Day 29 | 19.766 ± 20.8879 | 25.622 ± 36.4743 | 8.003 ± 6.1368 | 8.596 ± 9.2114 | 9.243 ± 5.1441 | 8.554 ± 7.6207 |
| Day 45 | 12.664 ± 7.2467 | 5.468 ± 4.1120 | 5.807 ± 5.8272 | 7.223 ± 3.0891 | 7.927 ± 5.3051 | 11.763 ± 11.1239 |
Change in the serum rates of TNF-α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline
| pg/mL | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 2/ 24 hours | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 4/ 72 hours | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 5 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 6 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 15 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 29 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
| Day 45 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 | 2.290 ± 0.0000 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 0.9 ± 0.74 | 1.3 ± 0.52 | 1.5 ± 1.05 | 0.7 ± 0.82 | 1.4 ± 0.55 | 1.2 ± 0.97 |
| Change Day 15 | -1.0 ± NA | -1.0 ± 0.82 | -1.0 ± NA | 0.0 ± NA | -1.0 ± 0.00 | -0.5 ± 0.55 |
| Change Day 29 | -1.0 ± NA | -1.3 ± 0.50 | -1.0 ± NA | 0.0 ± NA | -0.5 ± 0.71 | 0.0 ± 0.82 |
| Change Day 45 | -1.0 ± NA | -1.3 ± 0.58 | -1.0 ± NA | 0.0 ± NA | -0.5 ± 0.71 | 0.0 ± 0.0 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.0 ± 1.20 | 0.7 ± 0.82 | 1.3 ± 1.37 | 0.8 ± 1.17 | 1.0 ± 1.00 | 0.7 ± 1.00 |
| Change Day 15 | 0.0 ± NA | -0.5 ± 1.0 | 0.0 ± NA | 0.0 ± NA | 0.0 ± 0.00 | -0.3 ± 0.52 |
| Change Day 29 | 0.0 ± NA | -1.0 ± 0.82 | 0.0 ± NA | 0.0 ± NA | -0.5 ± 0.71 | -0.3 ± 0.50 |
| Change Day 45 | 0.0 ± NA | -1.3 ± 0.58 | 0.0 ± NA | 0.0 ± NA | -0.5 ± 0.71 | -0.3 ± 0.5 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.4 ± 0.74 | 1.8 ± 0.75 | 1.8 ± 1.17 | 1.3 ± 0.82 | 1.6 ± 1.14 | 1.8 ± 0.67 |
| Change Day 15 | 0.0 ± NA | -1.3 ± 0.96 | -1.0 ± NA | -1.0 ± NA | -1.5 ± 0.71 | -0.7 ± 0.82 |
| Change Day 29 | 0.0 ± NA | -1.3 ± 0.96 | -2.0 ± NA | -1.0 ± NA | -0.5 ± 0.71 | -0.3 ± 0.50 |
| Change Day 45 | 0.0 ± NA | -1.3 ± 1.15 | -2.0 ± NA | -1.0 ± NA | -0.5 ± 0.71 | -0.8 ± 0.96 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.2 ± 1.21 | 1.2 ± 0.98 | 1.7 ± 1.03 | 1.5 ± 1.05 | 2.2 ± 0.45 | 1.3 ± 0.50 |
| Change Day 15 | -1.0 ± NA | -0.3 ± 1.26 | -1.0 ± NA | -1.0 ± NA | -2.5 ± 0.71 | -0.5 ± 0.55 |
| Change Day 29 | 1.0 ± NA | -1.3 ± 0.96 | -1.0 ± NA | -1.0 ± NA | -0.5 ± 0.71 | -0.5 ± 0.58 |
| Change Day 45 | 0.0 ± NA | -1.7 ± 0.58 | -1.0 ± NA | -1.0 ± NA | -0.5 ± 0.71 | -1.0 ± 0.82 |
Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".
| units of the HAQ index | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Baseline value | 1.4 ± 0.99 | 1.0 ± 0.63 | 1.2 ± 1.17 | 1.0 ± 1.10 | 1.2 ± 1.10 | 0.4 ± 0.73 |
| Change Day 15 | -1.0 ± NA | -0.5 ± 0.58 | 0.0 ± NA | -1.0 ± NA | 0.0 ± 0.00 | -0.2 ± 0.41 |
| Change Day 29 | -1.0 ± NA | -1.0 ± 0.82 | 0.0 ± NA | -1.0 ± NA | -0.5 ± 0.71 | -0.3 ± 0.5 |
| Change Day 45 | -1.0 ± NA | -1.3 ± 0.58 | 0.0 ± NA | -1.0 ± NA | -1.0 ± 1.41 | 0.3 ± 1.26 |
Collected over The safety of the investigational product was assessed over a 60-day period of therapy and follow-up. The tables show AEs that developed from the start of therapy.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RPH - 4 mg | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| RPH - 20 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| RPH - 40 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| RPH - 80 mg | 0/6 (0%) | 2/6 (33.3%) | 3/6 (50%) |
| RPH - 160 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Voltaren® (Diclofenac) | 0/9 (0%) | 1/9 (11.1%) | 2/9 (22.2%) |
| Event | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| drug-induced liver injuryHepatobiliary disorders | 0/15 | 0/6 | 0/6 | 1/6 | 0/5 | 0/9 |
| Mycobacterium tuberculosis complex test positiveInvestigations | 0/15 | 0/6 | 0/6 | 1/6 | 0/5 | 0/9 |
| pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/15 | 0/6 | 0/6 | 1/6 | 0/5 | 0/9 |
| CellulitisInfections and infestations | 0/15 | 0/6 | 0/6 | 0/6 | 0/5 | 1/9 |
| Event | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) |
|---|---|---|---|---|---|---|
| Cholecystitis chronicHepatobiliary disorders | 0/15 | 0/6 | 0/6 | 2/6 | 0/5 | 0/9 |
| Gouty arthritisMusculoskeletal and connective tissue disorders | 5/15 | 1/6 | 1/6 | 1/6 | 1/5 | 0/9 |
| LeukocytosisBlood and lymphatic system disorders | 0/15 | 1/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| Sinus tachycardiaCardiac disorders | 0/15 | 0/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| AstheniaGeneral disorders | 0/15 | 0/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| Injection site erythemaGeneral disorders | 0/15 | 0/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| Injection site pruritusGeneral disorders | 0/15 | 0/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| Blood cholesterol increasedInvestigations | 0/15 | 0/6 | 0/6 | 0/6 | 1/5 | 0/9 |
| Blood creatinine increasedInvestigations | 1/15 | 0/6 | 1/6 | 0/6 | 1/5 | 1/9 |
| Blood triglycerides increasedInvestigations | 0/15 | 0/6 | 1/6 | 0/6 | 1/5 | 0/9 |
| Age, Continuous(years) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 52.3 (31 to 63) | 51.7 (46 to 60) | 42.8 (34 to 57) | 56.5 (41 to 78) | 53.6 (50 to 59) | 52.2 (42 to 61) | 51.5 (31 to 78) |
| Sex: Female, Male(Participants) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 0 | 0 | 2 | 3 |
| Male | 15 | 5 | 6 | 6 | 5 | 7 | 44 |
| Race/Ethnicity, Customized(Participants) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) | Total |
|---|---|---|---|---|---|---|---|
| Race — Caucasian/White | 15 | 6 | 6 | 6 | 5 | 9 | 47 |
| Race — other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Disease duration(years) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 8.13 (0.9 to 17.2) | 7.65 (0.1 to 17.3) | 8.04 (2.4 to 19.4) | 9.16 (0.9 to 15.9) | 13.55 (7.4 to 29.3) | 6.41 (0.1 to 12.5) | 8.82 (0.1 to 29.3) |
| Exact number of affected joints(number (of joints)) | RPH - 4 mg | RPH - 20 mg | RPH - 40 mg | RPH - 80 mg | RPH - 160 mg | Voltaren® (Diclofenac) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 5.3 (1 to 23) | 3.0 (1 to 5) | 5.7 (1 to 25) | 2.7 (1 to 5) | 6.2 (2 to 16) | 3.0 (1 to 7) | 4.32 (1 to 25) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Mar 2020, 23 months.
Results were first posted in Jul 2022, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goflikicept